Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of medications used primarily in the management of type 2 diabetes mellitus. It is a synthetic analog of human GLP-1, a natural incretin hormone. GLP-1 is released from the intestines in response to food intake and plays a crucial role in glucose metabolism. Lixisenatide was approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of type 2 diabetes. It is administered via subcutaneous injection. Early research also explored its potential role in weight management due to its effects on appetite and gastric emptying (FDA label, DrugBank).
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Sources referenced
- U.S. Food and Drug Administration (FDA) label
- European Medicines Agency (EMA) Summary of Product Characteristics (SmPC)
- DrugBank
- National Institutes of Health (NIH) Office of Dietary Supplements (ODS)
- Mayo Clinic
- PubChem
- Cochrane Review
- Examine.com
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the glp1 category or studied for the same goals.
